Jianmin Pharmaceutical Group Co Ltd

Jianmin Group released its 2026 interim report, with net profit attributable to the parent company of 177 million yuan, a decrease of 19.68% compared with the same period last year. The company's total operating revenue was 1.611 billion yuan, down 10.72% year-on-year; net cash inflow from operating activities was 120 million yuan, up 116.27% year-on-year. The latest asset-liability ratio was 40.04%, gross margin was 62.48%, ROE was 6.57%, and diluted earnings per share was 1.17 yuan.

Jianmin Group released its 2026 half-year report. First-half net profit attributable to the parent fell 19.7% year on year to 177 million yuan. Operating revenue was 1.61 billion yuan, down 10.7% year on year. Net profit attributable to the parent excluding non-recurring items was 153 million yuan, down 21.5% year on year. Net operating cash flow was 120 million yuan, up 116.3% year on year. Second-quarter operating revenue was 738 million yuan, down 19.1% year on year, and net profit attributable to the parent was 89.48 million yuan, down 19.0% year on year. The company said there was no material change in its main business. Pharmaceutical industry revenue and pharmaceutical distribution revenue fell 9.24% and 13.31% respectively.